What is ALS Phase 2B Study CK-2017357?

Category: Others

false

See also: Clinical Trial

NCT01378676 is a Phase 2B Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS). Other study ID number is CY 4024.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 3
Moderate 6
Mild 9
None 8

Commonly reported side effects and conditions associated with ALS Phase 2B Study CK-2017357

Side effect Patients
Dizziness 6
Fatigue 3
Lightheadedness 3
Nausea 2
Brain fog 1
Daytime tiredness 1

Show all 14 reported side effects

Dosages

Based on patients currently using ALS Phase 2B Study CK-2017357

Dosage Patients
375 mg daily 1

Why patients stopped taking ALS Phase 2B Study CK-2017357

Multiple reasons could be selected

Reason Patients
Course of treatment ended 5
Side effects too severe 4
Other 1
See all 10 patients who've stopped using ALS Phase 2B Study CK-2017357

Duration

Currently using ALS Phase 2B Study CK-2017357

Duration Patients
2 - 5 years 1

Stopped using ALS Phase 2B Study CK-2017357

Duration Patients
Less than 1 month 3
1 - 6 months 7
Adherence
Adherence Evaluations
Always 25
Usually 0
Sometimes 0
Never taken as prescribed 1
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 2
A little hard to take 3
Not at all hard to take 21
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 16
Not specified 10
Last updated:
There are no evaluations for ALS Phase 2B Study CK-2017357.